Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $138,571.86 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 15,414 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $8.99 per share, for a total transaction of $138,571.86. Following the completion of the acquisition, the director owned 16,638,150 shares of the company’s stock, valued at $149,576,968.50. This trade represents a 0.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Down 2.9%

NASDAQ:ARTV traded down $0.27 during trading hours on Tuesday, reaching $8.91. 780,946 shares of the company’s stock were exchanged, compared to its average volume of 355,699. The company has a market capitalization of $220.26 million, a P/E ratio of -2.52 and a beta of 2.40. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The business’s 50-day simple moving average is $8.98 and its two-hundred day simple moving average is $6.20.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARTV has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in Artiva Biotherapeutics in the fourth quarter worth approximately $341,000. Jane Street Group LLC bought a new stake in Artiva Biotherapeutics during the fourth quarter worth approximately $174,000. Landscape Capital Management L.L.C. bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $112,000. BNP Paribas Financial Markets boosted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period. Finally, Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics during the second quarter worth approximately $58,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.